Patent classifications
C07D241/14
CGRP Receptor Antagonists
The disclosures herein relate to novel compounds of formula
##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
CGRP Receptor Antagonists
The disclosures herein relate to novel compounds of formula
##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
CGRP receptor antagonists
The disclosures herein relate to novel compounds of formula ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
CGRP receptor antagonists
The disclosures herein relate to novel compounds of formula ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
CGRP receptor antagonists
The disclosures herein relate to novel compounds of formula ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
CGRP receptor antagonists
The disclosures herein relate to novel compounds of formula ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
CGRP Receptor Antagonists
The disclosures herein relate to novel compounds of formula
##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
Substituted piperazines as disrupters of AB42 oligomer formation
Described herein, inter alia, are certain substituted piperazines, for example, having the Formula 182, and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition. ##STR00001##
Compositions comprising a retinoid X receptor (RXR) agonist, a retinoic acid receptor (RAR) agonist, or a dual RXR/RAR agonist
The present invention relates to compositions comprising an RXR agonist, an RAR agonist, or a dual RXR/RAR agonist. The present invention further relates to methods of using the agonist compositions for treating or preventing dementia and cancer. In some embodiments, the dementia comprises Alzheimer's disease. In some embodiments, the cancer comprises leukemia.